James E Deerfield Mgmt L.P.... Net Worth

The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least $6.75 Million dollars as of 12 June 2017. James P owns over 110,447 units of Zafgen stock worth over $1,164,918 and over the last 9 years James sold ZFGN stock worth over $5,589,966.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James P ZFGN stock SEC Form 4 insiders trading

James has made over 4 trades of the Zafgen stock since 2016, according to the Form 4 filled with the SEC. Most recently James sold 110,447 units of ZFGN stock worth $705,756 on 12 June 2017.

The largest trade James's ever made was selling 1,341,499 units of Zafgen stock on 20 July 2016 worth over $4,440,362. On average, James trades about 394,840 units every 121 days since 2016. As of 12 June 2017 James still owns at least 1,176,685 units of Zafgen stock.

You can see the complete history of James P stock trades at the bottom of the page.

Insiders trading at Zafgen

Over the last 10 years, insiders at Zafgen have traded over $14,218,922 worth of Zafgen stock and bought 689,531 units worth $3,998,442 . The most active insiders traders include James E Deerfield Mgmt L.P...., Bruce Booth, and Kevin P Starr. On average, Zafgen executives and independent directors trade stock every 53 days with the average trade being worth of $87,516. The most recent stock trade was executed by Thomas E. Hughes on 28 June 2018, trading 32,000 units of ZFGN stock currently worth $320,000.

What does Zafgen do?

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Complete history of James P stock trades at Recro Pharma Inc and Zafgen

Zafgen executives and stock owners

Zafgen executives and other stock owners filed with the SEC include:

• Brian McVeigh,
  Chief Business Officer
• Frank Thomas,
  Independent Director
• Thomas Daniel,
  Independent Director
• Jonathan Leff,
  Director
• Thomas Hamilton,
  Director
• Priya Singhal,
  Head of Research and Development
• Michael Celano,
  Chief Financial Officer
• Carole Ben-Maimon,
  President, Chief Executive Officer, Director
• Joseph Truitt,
  Chairman of the Board
• Patrick Loustau,
  President
• Cameron Geoffrey Mc Donough,
  Director
• Frances K Heller,
  Director
• Robert J Perez,
  Director
• John L Lamattina,
  Director
• Dennis D Kim,
  Chief Medical Officer
• Alicia Secor,
  Chief Commercial Officer
• James E Deerfield Mgmt L.P....,
  
• Bruce Booth,
  Director
• Patricia L Allen,
  Chief Financial Officer
• James E Deerfield Mgmt L.P....,
  
• Jeffrey S. Hatfield,
  Chief Executive Officer
• Wendy Everett,
  Director
• Venture Fund Vii L P Atlas ...,
  
• Peter Barrett,
  Director
• Avi Y. Goldberg,
  Director
• Rock Ventures Lp Third Rock...,
  
• Rock Ventures Lp Third Rock...,
  
• Thomas E. Hughes,
  Chief Executive Officer
• Kevin P Starr,
  Director